Castle Biosciences (CSTL) to Release Earnings on Thursday

Castle Biosciences (NASDAQ:CSTL) will release its earnings data after the market closes on Thursday, May 2nd. Analysts expect Castle Biosciences to post earnings of ($0.37) per share for the quarter. Castle Biosciences has set its FY 2024 guidance at EPS.Parties that wish to register for the company’s conference call can do so using this link.

Castle Biosciences (NASDAQ:CSTL) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.74. Castle Biosciences had a negative net margin of 26.15% and a negative return on equity of 14.92%. The business had revenue of $66.12 million for the quarter, compared to analysts’ expectations of $51.32 million. On average, analysts expect Castle Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Castle Biosciences Stock Down 1.0 %

Castle Biosciences stock opened at $19.86 on Thursday. The company’s fifty day simple moving average is $21.30 and its 200-day simple moving average is $19.97. Castle Biosciences has a 12 month low of $9.26 and a 12 month high of $26.70. The stock has a market cap of $545.16 million, a P/E ratio of -9.19 and a beta of 0.93.

Wall Street Analyst Weigh In

CSTL has been the topic of several research analyst reports. Scotiabank boosted their price target on shares of Castle Biosciences from $33.00 to $37.00 and gave the company a “sector outperform” rating in a report on Friday, March 1st. KeyCorp boosted their price target on shares of Castle Biosciences from $25.00 to $28.00 and gave the company an “overweight” rating in a report on Friday, March 1st.

Insider Buying and Selling

In related news, insider Derek J. Maetzold sold 1,947 shares of the company’s stock in a transaction on Friday, April 12th. The shares were sold at an average price of $20.35, for a total value of $39,621.45. Following the completion of the sale, the insider now directly owns 65,418 shares in the company, valued at $1,331,256.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Castle Biosciences news, insider Derek J. Maetzold sold 1,947 shares of the business’s stock in a transaction on Friday, April 12th. The shares were sold at an average price of $20.35, for a total transaction of $39,621.45. Following the completion of the transaction, the insider now owns 65,418 shares of the company’s stock, valued at approximately $1,331,256.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Daniel Bradbury sold 2,400 shares of the business’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $20.45, for a total transaction of $49,080.00. Following the transaction, the director now directly owns 17,944 shares of the company’s stock, valued at approximately $366,954.80. The disclosure for this sale can be found here. Over the last three months, insiders sold 50,062 shares of company stock worth $1,051,065. Corporate insiders own 7.70% of the company’s stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.